TrialAmerican journal of respiratory and critical care medicine2021

Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More

Matthias Griese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.